A tighter look at the products that matter most to Regeneron Pharmaceuticals, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
Retinal disease biologic therapy
1 conceptEYLEA and EYLEA HD are aflibercept injectable anti-VEGF medicines used for serious retinal vascular diseases including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion.
Immunology biologic therapy
1 conceptDupixent is dupilumab, a monoclonal antibody therapy developed by Regeneron and Sanofi for diseases driven by type 2 inflammation, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD with an eosinophilic phenotype, and chronic spontaneous urticaria.
Paper trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Regeneron Pharmaceuticals · annual report
Primary annual source for business description, marketed blockbuster medicines, proprietary discovery platforms, and 2025 financial context.
Reviewed 2026-06-01
Regeneron Pharmaceuticals · investor relations
Primary investor release for 2025 product sales, Dupixent global sales, EYLEA/EYLEA HD sales, and profitability context.
Reviewed 2026-06-01
Regeneron Pharmaceuticals · product page
Official product listing used to confirm Regeneron's approved medicine portfolio and product names.
Reviewed 2026-06-01
CompaniesMarketCap · market data
Market-cap source specified in the intake manifest and used for ranking context.
Reviewed 2026-06-01
Stock Analysis · market data
Supplemental public market-data source for current market capitalization and valuation context.
Reviewed 2026-06-01